Skip to content

Clinical evaluation and network pharmacological study on the mechanism of Xiaochengqi Decoction in the treatment of Yangming Fu heat type of schizophrenia

Clinical evaluation and network pharmacological study on the mechanism of Xiaochengqi Decoction in the treatment of Yangming Fu heat type of schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057743
Enrollment
Unknown
Registered
2022-03-16
Start date
2022-03-12
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Yangming Fu heat type of schizophrenia

Interventions

Experimental group:On the basis of olanzapine treatment with Xiaochengqi decoction
Control group:Olanzapine treatment

Sponsors

The Second Affiliated Hospital of Xinxiang Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for Western Medicine: (1) Meet the diagnostic criteria for schizophrenia in the International Classification of Diseases (ICD-10); (2) Aged 18-55 years, gender unlimited; (3) Total score of PANSS >= 60; (4) Junior high school or above education level; (5) Signed by the patient's legal guardian or himself. 2. Inclusion criteria of TCM: (1) Main symptoms: hyperactivity, manic restlessness, disturbance and restlessness, destruction of objects beating and scolding, moving and much anger; (2) Concurrent symptoms: upset not sleep, mouth dirty spray people, dipsia drink, constipation, abdominal distension, abdominal pain, yellow tongue, yellow moss thick greasy, pulse is strong. The above main symptoms see two, concurrent symptoms see two, see the tongue pulse can be diagnosed.

Exclusion criteria

Exclusion criteria: 1. Evidence of a clinically significant, serious, uncontrolled physical disease; 2. Accompanied by other mental diseases, mental retardation or personality disorders; 3. Refractory schizophrenia; 4. Previous history of antipsychotic malignant syndrome; 5. Patients who have received non-convulsive electroconvulsive therapy in the last 6 months; 6. Previous history of alcohol and drug dependence and abuse; 7. Significant risk of suicide or uncontrollable violent impulsive behavior; 8. Patients with obvious visual and hearing impairment.

Design outcomes

Primary

MeasureTime frame
Positive and negative symptoms;Event related potential-p300;Event related potential-MMN;Functional near-infrared spectroscopy;

Secondary

MeasureTime frame
Montreal cognitive assessment (MoCA);TCM syndrome evaluation scale;Clinical global impression scale;

Countries

China

Contacts

Public ContactDeng Li

The Second Affiliated Hospital of Xinxiang Medical College

deng1009586@126.com+86 13409231712

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026